Skip to main content
Log in

A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

To accurately analyze the clinical characteristics of paroxysmal nocturnal hemoglobinuria (PNH) in different ethnic backgrounds, we retrieved all retrospective studies on clinical characteristics of PNH with a median follow-up period >60 months published after 2000, analyzed the clinical characteristics of PNH patients in Asia and European/America, and statistically compared enumeration data in these studies. We included 1665 patients in this analysis. The proportion of female patients in Asia was significantly lower than that in Europe/America (P = 0.000). Incidence rates of hemoglobinuria and thromboembolism in Asia were significantly lower than in Europe/America (both P values were 0.000). Within the subgroups of patients with thromboembolism, Asian patients had a higher proportion of arterial thrombosis while Western patients had a higher proportion of abdominal venous thrombosis. Bone marrow failure was not clearly defined in most studies. The proportion of patients with pancytopenia was higher in China than in France (P = 0.048). The total death rates were similar in both ethnic groups (P > 0.05). In Europe/America the major cause of death was thromboembolism and in Asian countries was serious infections. Differences in population characteristics of PNH patients among different ethnic groups indicate the possibility of differential pathogenesis and may be informative for treatment decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84(5):1387–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703–11.

    Article  CAS  PubMed  Google Scholar 

  3. Rosse WF. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood. 1990;75(8):1595–601.

    CAS  PubMed  Google Scholar 

  4. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–8.

    Article  CAS  PubMed  Google Scholar 

  5. Zhang ZN, Liu EK. Clinical features of paroxysmal nocturnal hemoglobinuria (PNH) in China as compared with those in United Kingdom. Zhonghua Nei Ke Za Zhi. 1991;30(5):276–9, 317.

    CAS  PubMed  Google Scholar 

  6. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83(3):193–207.

    Article  PubMed  Google Scholar 

  7. Le XF, Yang TY, Yang XY, Wang XM. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases. Chin Med J (Engl). 1990;103(11):885–9.

    CAS  Google Scholar 

  8. Kruatrachue M, Wasi P, Na-Nakorn S. Paroxysmal nocturnal haemoglobinuria in Thailand with special reference to as association with aplastic anaemia. Br J Haematol. 1978;39(2):267–76.

    Article  CAS  PubMed  Google Scholar 

  9. Richards SJ, Rawstron AC, Hillmen P. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry. 2000;42(4):223–33.

    Article  CAS  PubMed  Google Scholar 

  10. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 2000;114(3):459–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–43.

    Article  CAS  PubMed  Google Scholar 

  12. Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–8.

    Article  CAS  PubMed  Google Scholar 

  13. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–7.

    Article  CAS  PubMed  Google Scholar 

  14. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol. 2013;98(4):406–16.

    Article  CAS  PubMed  Google Scholar 

  15. Schrezenmeier H, Muus P, Socié G, Szer J, Urbano-Ispizua A, Maciejewski JP, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922–9.

    Article  PubMed  PubMed Central  Google Scholar 

  16. de Azambuja AP, Malvezzi M, Bitencourt MA, Oliveira MM, Medeiros LA, Pasquini R. Paroxysmal nocturnal hemoglobinuria clone in 103 Brazilian patients: diagnosis and classification. Rev Bras Hematol Hemoter. 2015;37(2):90–7.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Garcia Carvalho A, Ghidetti Mangas Catarino D, Xavier Carneiro T, Blumm Ferreira F, Gil Rizzatti E, Arruda M, et al. Clinical and laboratory features of 26 patients with paroxysmal nocturnal hemoglobinuria in Sao Paulo-Brazil. Haematologica. 2012;97(SUPPL. 1(704–4).

  18. Moyo VM, Mukhina GL, Garrett ES, Brodsky RA. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol. 2004;126(1):133–8.

    Article  CAS  PubMed  Google Scholar 

  19. Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97(6):749–57.

    Article  PubMed  Google Scholar 

  20. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. French Society of Hematology; French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–106.

    Article  PubMed  Google Scholar 

  21. Ge M, Li X, Shi J, Shao Y, Zheng Y. Clinical features and prognostic factors of Asian patients with paroxysmal nocturnal hemoglobinuria: results from a single center in China. Ann Hematol. 2012;91(7):1121–8.

    Article  PubMed  Google Scholar 

  22. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102(10):3587–91.

    Article  CAS  PubMed  Google Scholar 

  23. Zou N, Han B, Cai H, Xu Y, Wang X, Li RS, et al. Clinical features of 76 Chinese patients with paroxysmal nocturnal haemoglobinuria. Zhonghua Xue Ye Xue Za Zhi. 2012;33(6):471–4.

    PubMed  Google Scholar 

  24. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35(2):333–46.

    Article  PubMed  Google Scholar 

  25. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 1988;33(2):590–600.

    Article  CAS  PubMed  Google Scholar 

  26. Tang L, Hu Y. Ethnic diversity in the genetics of venous thromboembolism. Thromb Haemost. 2015;114(5):901–909.

    Article  PubMed  Google Scholar 

  27. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985–96.

    Article  CAS  PubMed  Google Scholar 

  28. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786–92.

    Article  CAS  PubMed  Google Scholar 

  29. Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85(8):553–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bing Han.

Additional information

F. Yu and Y. Du contributed equally to this article.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, F., Du, Y. & Han, B. A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America. Int J Hematol 103, 649–654 (2016). https://doi.org/10.1007/s12185-016-1995-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-016-1995-1

Keywords

Navigation